Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

OVID vs EVMN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OVID Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–2 Matrix Metrics)

OVID Overall Winner 6-Pillar Tally: OVID 3 – 2 EVMN (1 Tie) Matrix Metrics: OVID 7 – 2 EVMN

As of Nov 16, 2026, Ovid Therapeutics Inc. (OVID) is the stronger overall head-to-head candidate over Evommune, Inc. (EVMN) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OVID carries a Unified Composite Score of 43.5/100 (HOLD) at $2.40 (1.8x Forward P/E, -4693.7% operating margin), whereas EVMN carries 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: OVID earns the overall head-to-head edge with a stronger Unified Composite Score (43.5/100 HOLD vs. EVMN 30.0/100 SELL) and 0.98β · 97% Vol risk profile, whereas EVMN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OVID vs EVMN
OVID NASDAQ Head-to-Head Winner
Ovid Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.40
-5.51% 1D
Market Cap $479.4M
TTM Revenue $1.5M
Forward P/E 1.8x
Beta / 30D Vol 0.98β · 97% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 15.0 Fund 42.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.5 · SMA20: $2.52 · SMA50: $2.50
EVMN US Equity
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap $315.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 118% Vol
Unified Composite Score
30.0 / 100 SELL
Tech 50.0 Fund 35.0 Flow 69.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 52.2 · SMA20: $6.45 · SMA50: $7.47

6-Pillar Scorecard Institutional Category Breakdown (OVID 3 – 2 EVMN)

Columns: Metric · OVID · EVMN
1. Valuation Multiples OVID
Forward P/E 1.8x N/M
Trailing P/E 1.8x N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale OVID
Revenue Growth (YoY) -88.3% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.5M N/A
Market Cap $479.4M $315.5M
3. Profitability & Quality OVID
Gross Margin 100.0% N/A
Operating Margin -4693.7% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -35.4% -69.5%
4. Balance Sheet & Cash Flow EVMN
Cash Generation (TTM) -$58M -$75M
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.5M Net Cash $52M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EVMN
Options Structure Phase CONSOLIDATION SURGE
Current IV / %ile 131.0% (30th %ile) 209.0% (53rd %ile)
Put/Call OI Skew 0.07x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OVID (7) vs EVMN (2)
Institutional Metric OVID EVMN Criterion Row Edge
Market Capitalization
Scale
$479.4M $315.5M Larger Scale OVID
Trailing P/E Ratio
Valuation
1.8x N/M Lower Multiple OVID
Forward P/E Ratio
Valuation
1.8x N/M Lower Multiple OVID
Revenue Growth (YoY)
Growth
-88.3% +0.0% Higher Growth EVMN
Operating Margin (TTM)
Profitability
-4693.7% 0.0% Higher Margin EVMN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-35.4% -69.5% Higher ROE OVID
52-Week Range Position
Momentum
63% ($1–$3) 8% ($5–$33) Stronger Trend OVID
Beta / 30D Volatility
Risk Regime
0.98β · 97% Vol 1.05β · 118% Vol Lower Realized Risk OVID
Unified Institutional Score
Composite Signal
43.5 / 100 (HOLD) 30.0 / 100 (SELL) Higher Composite OVID
Trailing 12M Revenue (USD)
Operating Scale
$1.5M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$58M ($1.5M Net Cash) -$75M ($52M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EVMN +25.7 pp
OVID: +11.63% · EVMN: +37.33%
3M Horizon OVID +34.58 pp
OVID: -15.49% · EVMN: -50.07%
6M Horizon OVID +67.16 pp
OVID: -0.41% · EVMN: -67.57%
1Y Horizon OVID +161.03 pp
OVID: +100.0% · EVMN: -61.03%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OVID Revenue EVMN Revenue OVID Op. Margin EVMN Op. Margin Margin Leader
FY2020 $10M N/A -645.4% N/A OVID
FY2021 $210M N/A 59.6% N/A OVID
FY2022 $0M N/A -3696.4% N/A OVID
FY2023 $0M N/A -15122.7% N/A OVID
FY2024 $0M $10M -10933.7% -1000.2% EVMN
FY2025 $10M $10M -585.2% -623.6% OVID

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OVID CONSOLIDATION
150d in phase · OBV NEUTRAL
Current IV 131.0%
IV Percentile 30th %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OVID Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EVMN SURGE
5d in phase · OBV ACCUMULATION
Current IV 209.0%
IV Percentile 53rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact EVMN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OVID Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $479.4M market capitalization and -4693.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EVMN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $315.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OVID vs EVMN Key Questions & Quantitative Answers

As of Nov 16, 2026, Ovid Therapeutics Inc. (OVID) is the stronger overall head-to-head candidate over Evommune, Inc. (EVMN) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OVID carries a Unified Composite Score of 43.5/100 (HOLD) at $2.40 (1.8x Forward P/E, -4693.7% operating margin), whereas EVMN carries 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: OVID earns the overall head-to-head edge with a stronger Unified Composite Score (43.5/100 HOLD vs. EVMN 30.0/100 SELL) and 0.98β · 97% Vol risk profile, whereas EVMN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.

OVID leads the Growth & Scale pillar: OVID posts -88.3% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (100.0% gross margin, -4693.7% operating margin), compared with EVMN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), OVID cumulative revenue shifted +0.0% while EVMN shifted +0.0%. In operating R&D and SG&A reinvestment, OVID deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EVMN.

OVID screens cheaper on headline valuation multiples. OVID trades at 1.8x Forward P/E, 1.8x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas EVMN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OVID (-35.4% ROE) versus EVMN (-69.5% ROE) capital efficiency.

In options market volatility and institutional positioning, OVID carries 131.0% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.98β · 97% Vol realized risk). By comparison, EVMN carries 209.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.05β · 118% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.